Articles from Cellino

Ernst & Young LLP (EY US) has named Nabiha Saklayen, Ph.D., CEO and Co-Founder of Cellino, a winner of the Entrepreneur Of The Year® 2025 New England Award. Now celebrating its 40th year, Entrepreneur Of The Year is one of the most prestigious business awards programs in the world, recognizing visionary leaders who are redefining how business is done and making a lasting impact on their industries and communities.

Cellino, a leader in advanced biomanufacturing, today announced that its optical biomanufacturing technology for generating induced pluripotent stem cells (iPSCs) has received the FDA’s Advanced Manufacturing Technology (AMT) designation from the Center for Biologics Evaluation and Research (CBER). This prestigious designation highlights the transformative potential of Cellino's automated technology for scaling up high-quality iPSCs to industrialize next-generation regenerative therapies.

Cellino, a biotechnology company pioneering autonomous biomanufacturing for personalized regenerative medicine, today announced its expansion into the Asia-Pacific region through a strategic collaboration with Karis Bio, a leading South Korean cell therapy biotech. The partnership aims to industrialize the world’s first clinical-stage autologous induced pluripotent stem cell (iPSC)-derived cell therapy for peripheral artery disease (PAD) and coronary artery disease (CAD).

Cellino and Matricelf (TASE: MTLF) announced today a collaboration to accelerate the global biomanufacturing of personalized spinal cord injury treatments using Cellino’s Nebula™ technology combined with Matricelf’s breakthrough regenerative approach. This collaboration combines Cellino’s automated iPSC manufacturing with Matricelf’s double autologous 3D differentiation process, paving the way for scalable, patient-specific regenerative therapies.

Cellino today announced its collaboration with Mass General Brigham’s Gene and Cell Therapy Institute (GCTI) to launch the world’s first hospital-based autologous induced pluripotent stem cell (iPSC) Foundry. Powered by Cellino’s AI-driven Nebula technology, this initiative sets the stage for a nationwide network of decentralized biomanufacturing hubs designed to deliver personalized cell and tissue therapies directly at the point of care.

Cellino, a personalized regenerative medicine company developing an AI-guided laser editing platform for autologous cell-based therapies, today announced the appointment of industry pioneer Robert J. Palay, J.D., M.B.A., to the Cellino Board of Directors.

Cellino, a personalized regenerative medicine company developing an AI-guided laser editing platform for autologous cell-based therapies, today announced that its CEO Dr. Nabiha Saklayen has been awarded the first Tory Burch Fellowship at the International Genomics Institute (IGI).